Protagonist returns to profit in Q2 FY26 with net income of $162.85 million
PTGX•Pipeline and commercial update
- Rusfertide NDA remained under FDA priority review with an August 2026 PDUFA date; ICOTYDE posted its first full quarter of commercial sales.
Protagonist returns to profit in Q2 FY26
- Protagonist Therapeutics swung to GAAP net income of USD 162.85 million in Q2 2026 from a loss a year earlier; diluted EPS was USD 2.29.
- GAAP revenue climbed to USD 213.48 million from USD 5.55 million, driven mainly by Takeda opt-out payment recognition and development services.
- GAAP R&D expense rose to USD 42.06 million from USD 37.04 million; GAAP G&A increased to USD 12.65 million from USD 10.55 million.
- Cash, cash equivalents and marketable securities rose to USD 849.45 million at June 30 from USD 646 million at Dec. 31.
